
Platelet and Plasma Market
Platelet and Plasma Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
Platelet and Plasma Market Size and Trend Analysis
How Fast Will Platelet and Plasma Supply Grow Through 2033?
The global Platelet and Plasma market size is expected to be valued at US$ 18.6 billion in 2026 and projected to reach US$ 29.9 billion by 2033, growing at a CAGR of 7.02% between 2026 and 2033.
Between 2020 and 2025 the blood component supply chain expanded at an estimated 6.2% CAGR, after donor attendance fell sharply in 2020 and then recovered. Three factors carry the forecast. Demand for plasma-derived therapies, especially immunoglobulins used in primary and secondary immunodeficiency, keeps pulling fractionators to buy more litres of source plasma. Collection centre networks in the United States have been enlarged to meet that pull. Pathogen reduction and extended-storage processing raise the value of each platelet unit released, even where transfusion volumes are flat. The direction is steady volume growth, constrained less by clinical demand than by how many eligible donors can be recruited and retained.
Key Report Takeaways
- By Product Type: Source Plasma for Fractionation held 59.0% share in 2026, while Platelet Concentrates are projected to expand at a 7.6% CAGR through 2033, as pathogen-reduced apheresis units replace lower-value pooled buffy-coat preparations.
- By Collection Method: Apheresis Collection held 74.0% share in 2026, while Hybrid and Automated Multicomponent Collection is projected to expand at a 9.6% CAGR through 2033, because one automated session can yield plasma and two platelet doses together.
- By Processing Technology: Conventional Processing and Leukoreduction held 61.0% share in 2026, while Pathogen Reduction Technology is projected to expand at an 11.2% CAGR through 2033, following national adoption decisions in several European blood establishments.
- By End User: Plasma Fractionation Companies held 54.5% share in 2026, while Research and Diagnostic Laboratories are projected to expand at a 9.4% CAGR through 2033, driven by demand for human plasma reagents, control sera and cell-culture supplements.
- By Region: North America held 44.0% share in 2026, while Asia Pacific is projected to expand at an 8.9% CAGR through 2033, supported by new plasma collection programmes in China, India and Japan.
Global Platelet and Plasma Market Trends and Insights
Drivers Impact Analysis
Two forces account for most of the forecast expansion in platelet and plasma supply.
| Driver | Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
| Rising immunoglobulin consumption pulling fractionators toward more source plasma litres | High | North America, Europe, Asia Pacific | Long term (≥4 years) |
| Regulatory and clinical adoption of pathogen reduction raising value per platelet unit | Medium | Europe, North America | Medium term (2–4 years) |
Immunoglobulin Demand Pulls More Source Plasma Litres Into the Collection Network
Growth in plasma-derived therapy use is the single largest engine behind collection volumes. Immunoglobulin products treat primary immunodeficiencies and are also used in several immune-mediated neurological conditions, and diagnosed patient numbers have risen as awareness and testing improved. Because immunoglobulin yield per litre is finite, every additional treated patient translates directly into additional litres that fractionators must buy. That demand reaches the market as long-term supply contracts with collection centre operators.
The mechanism is a fixed biological conversion rate between donation and therapy. A fractionation plant cannot raise output without raising feedstock, so capacity planning starts with litres rather than with plant throughput. Albumin demand in China and clotting factor demand outside high-income markets add further pull. WHO guidance on blood availability and self-sufficiency has pushed national authorities to measure plasma supply against domestic need, which has made collection capacity a planning target rather than a by-product of whole blood donation.
Pathogen Reduction Adoption Raises the Realised Value of Each Platelet Dose
Pathogen reduction is changing platelet economics more than platelet volumes. Where a blood establishment adopts the technology, every treated dose carries an added disposable kit and illumination step, which raises the price charged to hospitals. Several European national services now treat all or most of their platelet supply this way, and uptake in North America has grown alongside bacterial risk control expectations. The result is value growth in a component whose transfusion volume is broadly stable.
The driver behind adoption is residual transfusion-transmitted infection risk and bacterial contamination of room-temperature platelets. The US Food and Drug Administration has set out bacterial risk control strategies for platelets that blood collectors must follow, and treated platelets are one accepted route to compliance. Treatment also allows some establishments to extend platelet shelf life, which reduces outdating. AABB standards for blood banks and transfusion services give hospitals a common reference for validating these processes.
Restraints Impact Analysis
Two structural limits temper the growth outlook for blood component supply.
| Restraint | Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
| Donor dependence and the geographic imbalance in source plasma collection | High | Europe, Asia Pacific, Latin America | Long term (≥4 years) |
| Compliance cost of donor screening, testing and cold chain for short-dated components | Medium | Global | Medium term (2–4 years) |
Donor Supply Imbalance Limits How Fast Plasma Volumes Can Be Increased
Supply is bounded by donors, not by processing capacity. A large majority of the world’s source plasma is collected in the United States, where frequent donation with compensation for time is permitted. Most European member states, and many countries elsewhere, operate voluntary non-remunerated donation with lower permitted donation frequency, so their collection per head is far smaller. National systems that cannot raise domestic litres remain dependent on imported feedstock, which exposes them to any disruption at a small number of collection networks.
The underlying cause is regulatory and cultural rather than technical. Donor compensation rules differ by member state across the European Union, and Regulation (EU) 2024/1938 preserves national discretion over what compensation is allowed. Donor eligibility criteria, deferral periods, haemoglobin and protein thresholds, and inter-donation intervals all cap the yield of an existing donor base. Recruiting new donors is slow and sensitive to local demographics.
Screening, Testing and Cold Chain Compliance Costs Compress Blood Centre Margins
Compliance costs absorb much of the price that blood establishments can charge. Every donation must be screened, tested, labelled, traced and stored under controlled conditions, and platelets add agitation and strict temperature control within a short shelf life. Outdating of unused platelet units is a direct loss, and the cost of discarded components falls on the collector rather than on the hospital. Many non-profit blood centres therefore operate on thin surpluses.
The specific cost sources are identifiable. Nucleic acid amplification testing and serological screening for transfusion-transmitted infections are performed per donation, with no volume relief. FDA regulations at 21 CFR Part 606 and 21 CFR Part 640 set manufacturing practice and component standards requiring validated equipment, qualified staff and documented quality systems. Apheresis collection consumes a single-use disposable set per session. Transport fleets, validated shippers and backup power complete a fixed cost base.
Market Opportunities
Domestic Plasma Collection Programmes Outside the United States Open a New Feedstock Pool
National plasma self-sufficiency programmes represent the clearest untapped revenue pool. Several governments have concluded that dependence on imported feedstock is a strategic risk, and have begun authorising new plasmapheresis centres, revising donation frequency rules or contracting operators to build networks. Each new centre adds recurring litres under long contracts, which is attractive revenue because it is volume-based and predictable rather than tied to a product launch.
Collection centre operators, national blood establishments and fractionators with contract manufacturing arrangements are positioned to capture this. The customer is usually a health ministry or national blood authority seeking secure supply of immunoglobulin and albumin for its own population. Regulation (EU) 2024/1938, which replaces Directive 2002/98/EC, strengthens supply continuity and crisis preparedness duties for member states, giving these programmes a legal anchor. Centre siting, donor retention and apheresis device availability determine how quickly litres actually arrive.
Cold-Stored and Extended Shelf-Life Platelets Create a Trauma and Rural Supply Segment
Cold-stored platelets open a revenue pool that room-temperature products cannot serve. Conventional platelet concentrates are held at 20 °C to 24 °C with agitation and expire within days, which makes them impractical for small hospitals, remote sites and pre-hospital care. Refrigerated platelets have a longer usable life and are of growing interest for actively bleeding patients, creating demand from settings that previously stocked none at all.
Trauma centres, military medical services and rural hospital networks are the natural customers, and blood establishments that can validate the process capture the supply contract. Supporting developments include FDA-recognised storage variations for cold-stored platelets and accumulating clinical experience in massive transfusion protocols. The segment remains small and its clinical positioning is still being defined through trials, so suppliers should treat it as an adjacent product line rather than a replacement for standard platelet inventory.
Segment Analysis
By Product Type: Source Plasma for Fractionation Leads While Platelet Concentrates Gain Value
Source Plasma for Fractionation held 59.0% of 2026 revenue. It leads because fractionators buy very large, contracted volumes of apheresis plasma to feed immunoglobulin and albumin production, and because a single donor can contribute far more plasma per year than whole blood. The United States supplies the majority of these litres through a dense commercial collection network.
Platelet Concentrates are the fastest-growing product type at a 7.6% CAGR to 2033. Growth is driven by value rather than volume, as single-donor apheresis units and pathogen-reduced doses replace pooled buffy-coat preparations and carry higher release prices.
Fresh Frozen Plasma and Plasma for Transfusion, together with Cryoprecipitate and Other Plasma Components, make up the balance and track surgical and obstetric activity. The implication for suppliers is that margin improvement now depends on component mix and processing technology, not simply on collecting more units.
By Collection Method: Apheresis Dominates While Multicomponent Sessions Expand Fastest
Apheresis Collection held 74.0% share in 2026 and is the backbone of modern plasma supply. Automated separation returns red cells to the donor, which allows far higher plasma volumes per session and more frequent donation than whole blood collection permits. It also yields a single-donor platelet dose that reduces recipient exposure compared with pooling several donors.
Hybrid and Automated Multicomponent Collection is the fastest-growing method at a 9.6% CAGR. Modern separators can take a double platelet dose plus plasma in one visit, raising yield per donor hour and easing the donor recruitment constraint that limits every blood establishment.
Whole Blood Derived Collection remains important for red cell supply and for recovered plasma sent to fractionation, particularly in countries without large plasmapheresis networks. The business consequence is that device placement and disposable kit contracts increasingly determine which collector can grow capacity.
By Processing Technology: Conventional Leukoreduction Leads as Pathogen Reduction Scales
Conventional Processing and Leukoreduction accounted for 61.0% of 2026 value. Universal leukoreduction is mandated or standard practice in most high-income blood systems, is comparatively inexpensive per unit, and is embedded in existing component preparation lines, so it remains the default for the bulk of output.
Pathogen Reduction Technology is the fastest-growing processing route at an 11.2% CAGR to 2033. Adoption has moved from selective use to whole-inventory treatment in several European national services, and interest in North America has grown alongside bacterial risk control expectations for platelets.
Cold-Stored and Extended Shelf-Life Platelets and Freeze-Dried and Lyophilized Plasma are small but strategically important, because both address logistics rather than safety. For blood establishments the practical implication is a rising capital and consumable cost base per unit, which must be recovered through hospital service charges.
By End User: Fractionation Companies Buy the Most While Laboratories Grow Quickest
Plasma Fractionation Companies held 54.5% of 2026 purchases. They lead because industrial-scale plants consume continuous, contracted feedstock volumes, and because the therapies they produce command prices that support sustained investment in collection capacity upstream.
Research and Diagnostic Laboratories are the fastest-growing end user at a 9.4% CAGR. Demand comes from human plasma used as assay matrix and control material, platelet lysate as a serum substitute in cell culture, and reference reagents for diagnostics manufacturing, all of which require characterised, traceable human material.
Hospitals and Transfusion Services and Blood Banks and Blood Centers account for the remainder and set clinical specification. The implication for collectors is that a single donation stream now serves two different buyers, with very different contracting behaviour and price sensitivity.
Geography Analysis
Which Region Is Leading the Platelet and Plasma Market?
North America leads with 44.0% share of the platelet and plasma market in 2026. The United States supplies almost all of it and collects the majority of the world’s source plasma, through a large commercial plasmapheresis network concentrated in border states and population centres. Canada contributes a smaller volume and has been expanding domestic plasma collection to reduce import reliance.
Regulation explains much of the structure. FDA blood regulations at 21 CFR Part 606 and 21 CFR Part 640 set manufacturing and component standards, while AABB accreditation governs hospital transfusion practice. The move to individual donor assessment in 2023 widened the eligible donor pool without lowering screening rigour. The main change ahead is continued centre build-out and automation of donor qualification, which raises throughput per site rather than adding new sites.
Europe Balances Voluntary Donation Rules Against Plasma Import Dependence
Europe holds 25.0% of the 2026 market. Germany, Austria, Czechia and Hungary account for most plasmapheresis activity, because their national rules permit higher donation frequency and compensation for donor time, while France, Italy and Spain operate largely public, voluntary systems with lower collection per head.
The regulatory framework is being rewritten. Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin replaces Directive 2002/98/EC and the tissues and cells directives, and adds obligations on supply continuity, donor protection and registration of establishments. Member states retain discretion over donor compensation, so the collection imbalance inside the bloc is unlikely to disappear quickly. The clearest opportunity is public-private plasma centre partnerships aimed at reducing imported feedstock.
Which Region Is Growing Fastest in the Platelet and Plasma Market?
Asia Pacific is the fastest-growing geography at an 8.9% CAGR between 2026 and 2033, from 21.0% share in 2026. China drives most of that, with a large and tightly regulated domestic plasma collection station system and persistent albumin demand. Japan operates a mature, largely self-sufficient system, while India, South Korea and Australia are expanding apheresis capacity and component standards.
Two local factors shape the trajectory. Plasma collection station licensing in China is controlled provincially, so capacity growth is administrative as much as commercial. Blood safety upgrades, including wider nucleic acid testing and leukoreduction, are raising cost per unit and shifting output toward higher-specification components. The main constraint is donor recruitment in countries where voluntary donation rates per thousand population remain well below high-income norms.
Latin America Builds Capacity Around National Blood Policy Reform
Latin America represents 6.0% of the 2026 market. Brazil, Argentina, Mexico and Colombia account for most activity, with Brazil operating a large public blood network and a state-linked fractionation capability intended to convert domestic plasma into finished therapies rather than exporting feedstock.
Barriers are mainly structural. Collection is fragmented across many small hospital-based services, apheresis penetration is low outside major cities, and currency exposure makes imported disposables and test kits expensive. Voluntary donation rates vary widely between countries, and replacement donation still accounts for a meaningful share of supply in several systems. The most significant change would be regional consolidation of testing and processing into fewer, larger centres, which several national authorities have identified as a route to both quality and cost improvement.
Middle East & Africa Supply Concentrates in Gulf and North African Blood Services
Middle East & Africa accounts for 4.0% of 2026 revenue, the smallest regional share. Saudi Arabia, the United Arab Emirates, Qatar and Israel operate well-funded national blood services with apheresis platforms and modern testing, and Egypt, Morocco and South Africa run the largest programmes elsewhere in the region.
Constraints are severe beyond those clusters. Many sub-Saharan countries collect far fewer donations per thousand population than WHO considers consistent with basic transfusion need, rely heavily on family replacement donors, and lack the cold chain and testing infrastructure for routine component separation. Platelet availability is especially limited because of its short shelf life. The main opportunity is national blood service centralisation funded under health investment plans, which brings component production and quality systems into a smaller number of capable facilities.
Competitive Landscape
The platelet and plasma market is moderately concentrated, and concentration differs sharply by activity. Commercial source plasma collection is dominated by a small number of vertically integrated fractionators that operate their own centre networks to secure feedstock, which gives them scale in both collection and downstream manufacturing. Transfusion component supply, by contrast, is fragmented and largely non-commercial, delivered by national blood services, regional non-profit blood centres and hospital transfusion services. A third group supplies the technology layer: apheresis platforms, disposable kits, pathogen reduction systems, screening assays and cold chain equipment. Consolidation has been steadiest among collection centre operators, where scale lowers the cost per litre.
Competition is based on different factors in each layer. Collection operators compete on donor recruitment and retention, centre location, visit time and compliance record. Technology suppliers compete on yield per donor session, procedure time, disposable cost, validated shelf-life claims and integration with blood establishment computer systems. Blood establishments themselves compete less on price than on reliability of supply, inventory service levels and the ability to deliver specialised components such as human leucocyte antigen matched platelets. New entrants have appeared mainly as independent plasma collection networks that sell feedstock to fractionators under supply agreements.
Strategic activity centres on securing litres and lowering cost per donation. Suppliers have expanded centre footprints, invested in donor-facing digital scheduling and qualification, extended apheresis device platforms to multicomponent protocols, and pursued contract fractionation arrangements with national authorities seeking domestic supply. Technology vendors have broadened pathogen reduction into additional components and worked to align claims with national regulatory requirements.
Strategic direction is converging on three themes: feedstock security, automation of donor qualification and collection, and processing technologies that extend shelf life or reduce wastage across the component inventory.
Recent Industry Developments
- May 2010: The World Health Assembly adopted resolution WHA63.12 on availability, safety and quality of blood products – it urged member states to build nationally coordinated, voluntary unpaid donation systems and to work toward self-sufficiency in plasma-derived medicinal products.
- April 2020: The US Food and Drug Administration issued revised recommendations shortening several blood donor deferral periods, including the deferral for men who have sex with men from twelve months to three months – it enlarged the eligible donor pool during an acute supply shortage.
- May 2023: The US Food and Drug Administration published final guidance introducing individual donor assessment for blood donor eligibility, replacing time-based deferrals based on sexual orientation – it changed donor screening questionnaires across every United States collection establishment.
- June 2024: The European Parliament and the Council of the European Union adopted Regulation (EU) 2024/1938 on standards of quality and safety for substances of human origin intended for human application – it replaces Directive 2002/98/EC and the tissues and cells directives, and applies from 2027.
Companies Covered in the Report
Grifols, S.A.
CSL Limited
Takeda Pharmaceutical Company Limited
Octapharma AG
Terumo Blood and Cell Technologies
Haemonetics Corporation
Fresenius Kabi AG
Cerus Corporation
Macopharma SAS
Kedrion S.p.A.
ADMA Biologics, Inc.
Japan Blood Products Organization
Platelet and Plasma Market Report Scope
| Metric | Value |
| Study Period | 2020–2033 |
| Market Size 2026 | US$ 18.6 Billion |
| Market Size 2033 | US$ 29.9 Billion |
| CAGR 2026–2033 | 7.02% |
| Absolute Dollar Opportunity | US$ 11.3 Billion |
| Largest Market | North America (44.0% share in 2026) |
| Fastest-Growing Market | Asia Pacific (8.9% CAGR 2026–2033) |
| Market Concentration | Medium |
| Major Players | Grifols, S.A., CSL Limited, Takeda Pharmaceutical Company Limited, Octapharma AG, Terumo Blood and Cell Technologies |
Platelet and Plasma Market Segmentation
Product Type
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
Collection Method
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
Processing Technology
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
End User
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Executive Summary
- Global Platelet and Plasma Market Snapshot
- Market Size and Trend Analysis 2020–2033
- Historical Growth 2020–2025
- Base Year 2025
- Forecast Outlook 2026–2033
- Key Report Takeaways
- Market Overview
- Market Definition and Report Scope
- Market Dynamics
- Drivers
- Immunoglobulin Demand Pulls More Source Plasma Litres Into the Collection Network
- Pathogen Reduction Adoption Raises the Realised Value of Each Platelet Dose
- Restraints
- Donor Supply Imbalance Limits How Fast Plasma Volumes Can Be Increased
- Screening, Testing and Cold Chain Compliance Costs Compress Blood Centre Margins
- Market Opportunities
- Domestic Plasma Collection Programmes Outside the United States Open a New Feedstock Pool
- Cold-Stored and Extended Shelf-Life Platelets Create a Trauma and Rural Supply Segment
- Drivers
- Segment Analysis
- By Product Type: Source Plasma for Fractionation Leads While Platelet Concentrates Gain Value
- By Collection Method: Apheresis Dominates While Multicomponent Sessions Expand Fastest
- By Processing Technology: Conventional Leukoreduction Leads as Pathogen Reduction Scales
- By End User: Fractionation Companies Buy the Most While Laboratories Grow Quickest
- Global Platelet and Plasma Market Outlook, 2020–2033
- Global Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
- Global Platelet and Plasma Market Outlook, by Collection Method, Value (US$ Billion), 2020–2033
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
- Global Platelet and Plasma Market Outlook, by Processing Technology, Value (US$ Billion), 2020–2033
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
- Global Platelet and Plasma Market Outlook, by End User, Value (US$ Billion), 2020–2033
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
- Global Platelet and Plasma Market Outlook, by Region, Value (US$ Billion), 2020–2033
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- Global Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- North America Platelet and Plasma Market Outlook, 2020–2033
- Regional Market Leadership
- North America Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
- North America Platelet and Plasma Market Outlook, by Collection Method, Value (US$ Billion), 2020–2033
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
- North America Platelet and Plasma Market Outlook, by Processing Technology, Value (US$ Billion), 2020–2033
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
- North America Platelet and Plasma Market Outlook, by End User, Value (US$ Billion), 2020–2033
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
- North America Platelet and Plasma Market Outlook, by Country, Value (US$ Billion), 2020–2033
- United States Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- United States Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- United States Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- United States Platelet and Plasma Market Outlook, by End User, 2020–2033
- Canada Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Canada Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Canada Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Canada Platelet and Plasma Market Outlook, by End User, 2020–2033
- Europe Platelet and Plasma Market Outlook, 2020–2033
- Europe Balances Voluntary Donation Rules Against Plasma Import Dependence
- Europe Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
- Europe Platelet and Plasma Market Outlook, by Collection Method, Value (US$ Billion), 2020–2033
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
- Europe Platelet and Plasma Market Outlook, by Processing Technology, Value (US$ Billion), 2020–2033
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
- Europe Platelet and Plasma Market Outlook, by End User, Value (US$ Billion), 2020–2033
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
- Europe Platelet and Plasma Market Outlook, by Country, Value (US$ Billion), 2020–2033
- Germany Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Germany Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Germany Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Germany Platelet and Plasma Market Outlook, by End User, 2020–2033
- Austria Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Austria Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Austria Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Austria Platelet and Plasma Market Outlook, by End User, 2020–2033
- Czechia Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Czechia Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Czechia Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Czechia Platelet and Plasma Market Outlook, by End User, 2020–2033
- Hungary Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Hungary Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Hungary Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Hungary Platelet and Plasma Market Outlook, by End User, 2020–2033
- France Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- France Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- France Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- France Platelet and Plasma Market Outlook, by End User, 2020–2033
- Italy Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Italy Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Italy Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Italy Platelet and Plasma Market Outlook, by End User, 2020–2033
- Spain Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Spain Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Spain Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Spain Platelet and Plasma Market Outlook, by End User, 2020–2033
- Asia Pacific Platelet and Plasma Market Outlook, 2020–2033
- Regional Growth Outlook
- Asia Pacific Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
- Asia Pacific Platelet and Plasma Market Outlook, by Collection Method, Value (US$ Billion), 2020–2033
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
- Asia Pacific Platelet and Plasma Market Outlook, by Processing Technology, Value (US$ Billion), 2020–2033
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
- Asia Pacific Platelet and Plasma Market Outlook, by End User, Value (US$ Billion), 2020–2033
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
- Asia Pacific Platelet and Plasma Market Outlook, by Country, Value (US$ Billion), 2020–2033
- China Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- China Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- China Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- China Platelet and Plasma Market Outlook, by End User, 2020–2033
- Japan Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Japan Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Japan Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Japan Platelet and Plasma Market Outlook, by End User, 2020–2033
- India Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- India Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- India Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- India Platelet and Plasma Market Outlook, by End User, 2020–2033
- South Korea Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- South Korea Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- South Korea Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- South Korea Platelet and Plasma Market Outlook, by End User, 2020–2033
- Australia Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Australia Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Australia Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Australia Platelet and Plasma Market Outlook, by End User, 2020–2033
- Latin America Platelet and Plasma Market Outlook, 2020–2033
- Latin America Builds Capacity Around National Blood Policy Reform
- Latin America Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
- Latin America Platelet and Plasma Market Outlook, by Collection Method, Value (US$ Billion), 2020–2033
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
- Latin America Platelet and Plasma Market Outlook, by Processing Technology, Value (US$ Billion), 2020–2033
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
- Latin America Platelet and Plasma Market Outlook, by End User, Value (US$ Billion), 2020–2033
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
- Latin America Platelet and Plasma Market Outlook, by Country, Value (US$ Billion), 2020–2033
- Brazil Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Brazil Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Brazil Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Brazil Platelet and Plasma Market Outlook, by End User, 2020–2033
- Argentina Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Argentina Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Argentina Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Argentina Platelet and Plasma Market Outlook, by End User, 2020–2033
- Mexico Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Mexico Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Mexico Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Mexico Platelet and Plasma Market Outlook, by End User, 2020–2033
- Colombia Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Colombia Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Colombia Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Colombia Platelet and Plasma Market Outlook, by End User, 2020–2033
- Middle East & Africa Platelet and Plasma Market Outlook, 2020–2033
- Middle East & Africa Supply Concentrates in Gulf and North African Blood Services
- Middle East & Africa Platelet and Plasma Market Outlook, by Product Type, Value (US$ Billion), 2020–2033
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
- Middle East & Africa Platelet and Plasma Market Outlook, by Collection Method, Value (US$ Billion), 2020–2033
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
- Middle East & Africa Platelet and Plasma Market Outlook, by Processing Technology, Value (US$ Billion), 2020–2033
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
- Middle East & Africa Platelet and Plasma Market Outlook, by End User, Value (US$ Billion), 2020–2033
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
- Middle East & Africa Platelet and Plasma Market Outlook, by Country, Value (US$ Billion), 2020–2033
- Saudi Arabia Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Saudi Arabia Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Saudi Arabia Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Saudi Arabia Platelet and Plasma Market Outlook, by End User, 2020–2033
- United Arab Emirates Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- United Arab Emirates Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- United Arab Emirates Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- United Arab Emirates Platelet and Plasma Market Outlook, by End User, 2020–2033
- Qatar Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Qatar Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Qatar Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Qatar Platelet and Plasma Market Outlook, by End User, 2020–2033
- Israel Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Israel Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Israel Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Israel Platelet and Plasma Market Outlook, by End User, 2020–2033
- Egypt Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Egypt Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Egypt Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Egypt Platelet and Plasma Market Outlook, by End User, 2020–2033
- Morocco Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- Morocco Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- Morocco Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- Morocco Platelet and Plasma Market Outlook, by End User, 2020–2033
- South Africa Platelet and Plasma Market Outlook, by Product Type, 2020–2033
- South Africa Platelet and Plasma Market Outlook, by Collection Method, 2020–2033
- South Africa Platelet and Plasma Market Outlook, by Processing Technology, 2020–2033
- South Africa Platelet and Plasma Market Outlook, by End User, 2020–2033
- Competitive Landscape
- Market Concentration and Supplier Participation
- Competitive Factors and Strategic Direction
- Recent Industry Developments
- World Health Assembly Blood Product Quality Resolution May 2010
- FDA Blood Donor Deferral Revision April 2020
- FDA Individual Donor Assessment Guidance May 2023
- EU Substances of Human Origin Regulation Adoption June 2024
- Company Profiles
- Grifols, S.A.
- CSL Limited
- Takeda Pharmaceutical Company Limited
- Octapharma AG
- Terumo Blood and Cell Technologies
- Haemonetics Corporation
- Fresenius Kabi AG
- Cerus Corporation
- Macopharma SAS
- Kedrion S.p.A.
- ADMA Biologics, Inc.
- Japan Blood Products Organization
- Appendix
- Research Methodology
- Report Assumptions
- Acronyms and Abbreviations
Product Type
- Platelet Concentrates
- Fresh Frozen Plasma and Plasma for Transfusion
- Source Plasma for Fractionation
- Cryoprecipitate and Other Plasma Components
Collection Method
- Apheresis Collection
- Whole Blood Derived Collection
- Hybrid and Automated Multicomponent Collection
Processing Technology
- Conventional Processing and Leukoreduction
- Pathogen Reduction Technology
- Cold-Stored and Extended Shelf-Life Platelets
- Freeze-Dried and Lyophilized Plasma
End User
- Plasma Fractionation Companies
- Hospitals and Transfusion Services
- Blood Banks and Blood Centers
- Research and Diagnostic Laboratories
Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Our Research Methodology
Considering the volatility of business today, traditional approaches to strategizing a game plan can be unfruitful if not detrimental. True ambiguity is no way to determine a forecast. A myriad of predetermined factors must be accounted for such as the degree of risk involved, the magnitude of circumstances, as well as conditions or consequences that are not known or unpredictable. To circumvent binary views that cast uncertainty, the application of market research intelligence to strategically posture, move, and enable actionable outcomes is necessary.
View Methodology
Quality Assured
Rigorous Validation Process

Confidentiality Assured
End-to-end Data Security

Custom Research Services
Tailored To Your Objectives
FAQs
The market is valued at US$ 18.6 billion in 2026, covering collection, processing, testing and distribution of platelet concentrates and human plasma worldwide.
Revenue is projected to reach US$ 29.9 billion by 2033 at a 7.02% CAGR, an absolute dollar opportunity of US$ 11.3 billion over the period.
Source Plasma for Fractionation leads with 59.0% share in 2026, because fractionators contract very large apheresis plasma volumes for immunoglobulin and albumin production.
Pathogen Reduction Technology grows fastest at an 11.2% CAGR through 2033, as European national blood services move toward treating their whole platelet inventory.
North America leads with 44.0% share in 2026, and concentration is medium, with commercial plasma collection far more consolidated than transfusion component supply.
Related Reports
Varicose Vein Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
Explore the varicose vein market outlook for 2026–2033, covering treatments, products, end users, regional trends, and leading companies.
AI in Healthcare Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
Explore the AI in healthcare market outlook for 2026–2033, covering components, applications, end users, regional trends, and key companies.
Medical Case Management Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
The global medical case management market is valued at US$5.98 billion in 2026, reaching US$9.26 billion by 2033, growing at a 6.4% CAGR
Drug Discovery Informatics Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
Drug discovery informatics market is forecast to grow from US$ 3.7 billion in 2026 to US$ 6.9 billion by 2033 at 9.3% CAGR, driven by AI and cloud adoption.
Medical Device Security Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
The global medical device security market is valued at US$6.8 billion in 2026, reaching US$12.0 billion by 2033, growing at an 8.4% CAGR
Healthcare IT Integration Market Size, Share, Insights, Competitive Landscape, and Forecast 2026 to 2033
The global healthcare IT integration market is valued at US$4.9 billion in 2026, reaching US$10.6 billion by 2033, growing at an 11.7% CAGR